These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 29030733

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
    Ambrin G, Kumar R, Singh BR.
    Toxicon; 2018 Mar 15; 144():34-41. PubMed ID: 29309744
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
    Lam KH, Sikorra S, Weisemann J, Maatsch H, Perry K, Rummel A, Binz T, Jin R.
    Pathog Dis; 2018 Jun 01; 76(4):. PubMed ID: 29688327
    [Abstract] [Full Text] [Related]

  • 6. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.
    Gul N, Smith LA, Ahmed SA.
    PLoS One; 2010 Sep 22; 5(9):e12872. PubMed ID: 20877571
    [Abstract] [Full Text] [Related]

  • 7. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
    Kohda T, Tsukamoto K, Torii Y, Kozaki S, Mukamoto M.
    Microbiol Immunol; 2020 Jul 22; 64(7):502-511. PubMed ID: 32301520
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.
    Bradshaw M, Tepp WH, Whitemarsh RC, Pellett S, Johnson EA.
    Appl Environ Microbiol; 2014 Dec 22; 80(23):7415-22. PubMed ID: 25239905
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants.
    Jensen MJ, Smith TJ, Ahmed SA, Smith LA.
    Toxicon; 2003 May 22; 41(6):691-701. PubMed ID: 12727273
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins.
    Sharma SK, Singh BR.
    Biochemistry; 2004 Apr 27; 43(16):4791-8. PubMed ID: 15096048
    [Abstract] [Full Text] [Related]

  • 17. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
    Ayyar BV, Aoki KR, Atassi MZ.
    Infect Immun; 2015 Apr 27; 83(4):1465-76. PubMed ID: 25624352
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.